A Study to Assess the Relative Bioavailability of Different Subcutaneous Formulations ofAZD6234

NCT07220954 ↗

Phase 1 Recruiting 21 enrolled AstraZeneca Quotient Sciences · collab

RandomizedCrossoverOpen-labelTreatment

Summary

This study in healthy volunteers aims to compare blood levels and side effects after administration of different formulations of AZD6234. This study will take place at one site in Nottingham, United Kingdom, and will enrol 21 healthy men and women aged 18-55 years.

Timeline

Start: 2025-11-11
Primary completion: 2026-09-09
Completion: 2027-04-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	AZD6234	Small activating RNA (saRNA)	—	Subcutaneous

Indications

No indication recorded.